Physicians' Academy for Cardiovascular Education

Is inflammation reduction key for targeting residual risk, beyond lowering LDL-c?

3' education - Oct. 18, 2014 - Snapshot 2014 - Prof. Paul M Ridker, MD



Dr. Paul Ridker, Boston describes the different inflammatory pathways and ongoing clinical trials targeting inflammation
Recorded during the PAC Snapshot session in Barcelona 2014

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: